Related Articles
Molecular biomarkers and integrated pathological diagnosis in the reclassification of gliomas
IDH1 mutation of gliomas with long-term survival analysis
IDH1/2 mutation is a prognostic marker for survival and predicts response to chemotherapy for grade II gliomas concomitantly treated with radiation therapy
S100A6 is a potential diagnostic and prognostic biomarker for human glioma
Gene expression profiling and the isocitrate dehydrogenase mutational landscape of temozolomide‑resistant glioblastoma